share_log

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

生物技術日報：安進、吉利德去購物，爲處於早期乳腺癌的阿斯利康的Lynparza點頭，阿爾茨海默氏相關幻覺候選人的決策日
Benzinga Real-time News ·  2022/08/04 21:10
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要：
Stocks In Focus
焦點股票
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer
阿斯利康/默克的Lynparza在早期乳腺癌方面獲得歐洲的認可
The European Union has approved AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc's (NYSE:MRK) Lynparza (olaparib) for human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
歐盟已批准阿斯利康有限公司（納斯達克股票代碼：AZN）和默克公司的(NYSE: MRK) Lynparza（olaparib）用於先前接受過新輔助或輔助化療治療的人表皮生長因子受體2（HER2）陰性的高危早期乳腺癌。
The approval for Lynparza comes as monotherapy or in combination with endocrine therapy for the adjuvant treatment in the breast cancer setting with germline BRCA1/2 mutations.
Lynparza的批准是單一療法或與內分泌療法聯合使用，用於具有種系BRCA1/2突變的乳腺癌環境中的輔助治療。
Syros Bone Marrow Cancer Candidate Poised To Get...
賽羅斯骨髓癌候選...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論